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Abstract
Prostate cancer is the most common malignancy of men. Treatment options include 
radiotherapy with or without hormonal manipulation and radical prostatectomy. 
However, there is no effective treatment for disseminated disease. A hallmark of 
malignancy is abnormal metabolism which also confers survival advantages and 
contributes to resistance to therapy. In response to exposure to ionizing radiation, 
metabolic pathways are activated which can protect the cell from irreversible injury. 
Tumor cell glycolytic activity is elevated and correlates with aggressiveness and radio 
resistance, indicating that targeting glucose metabolism may sensitize cancer cells to 
radiation. We have demonstrated that the clonogenic kill of PC3 cells induced by 
exposure to x-rays was enhanced by the glycolytic inhibitor 2-deoxyglucose (2DG). In 
contrast, treatment with 2DG failed to inhibit growth of multicellular spheroids derived 
from LNCaP cells. However, 2DG treatment, in the absence of irradiation, induced similar 
toxicity to PC3 and LNCaP cells cultured as monolayers. Radiation-induced cell cycle 
arrest was prevented by the simultaneous administration of 2DG in both cell lines, 
indicating a possible mechanism underlying sensitization. Therefore, we hypothesise 
that observed differences in cellular response to incubation with 2DG in the presence or 
absence of ionizing radiation resulted from variation in metabolic processes between 
tumor cell types. We conclude that inhibition of glucose metabolism by 2DG is an 
effective method for sensitizing prostate cancer cells to experimental radiotherapy and 
that this may occur by preventing DNA repair during radiation-induced cell cycle arrest.
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Introduction
Prostate cancer is the most common cancer amongst men. Prostate cancer is a 
disease that predominantly affects men over the age of 50 and the number of deaths 
resulting from this disease is predicted to rise in the coming years as a result of increased 
life expectancy. Radiotherapy is widely used in the treatment of prostate cancer patients, 
with or without hormonal manipulation and radical prostatectomy. However, damage 
to neighbouring normal organs limits the radiation dose which can be delivered. 
Although there is currently no effective treatment for disseminated disease, it is likely 
that the efficacy of radiotherapy can be enhanced by combination with radiosensitizing 
agents. A hallmark of malignancy is abnormal metabolism which generates biomass and 
energy for proliferation, migration and cell signalling. Such metabolic adaption by cancer 
cells also confers survival advantages to these cells and contributes to resistance to 
therapy. Furthermore, in response to exposure to ionizing radiation, metabolic pathways 
are activated which can protect the cell from irreversible injury [1]. Interestingly, it has 
been reported that radioresistant cancer cells have altered components of energy 
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metabolism compared with their radiosensitive counterparts 
[2]. This suggests that targeting one or more of these metabolic 
pathways may sensitize cancer cells to radiation.
One characteristic of this metabolic re-programming is 
increased glucose consumption and lactate production, even in 
the presence of oxygen. This is termed aerobic glycolysis or the 
Warburg effect [3, 4]. Tumor cell glycolytic activity results in 
accumulation of pyruvate, lactate and glutathione, which 
counteract reactive oxygen species (ROS) [5], and correlates with 
tumor aggressiveness and radioresistance [6]. Targeting glucose 
metabolism, using the glycolytic inhibitor 2-deoxyglucose (2DG), 
is toxic to cancer cells and sensitises them to radiation [6-10]. 
2DG competes with glucose for transmembrane transport. 
However, after hexokinase converts 2DG into 2-deoxyglucose-6-
phosphate, it cannot be further metabolized. Cancer cells are 
more susceptible to inhibition of glucose metabolism in the 
presence of increased ROS [11], reflecting the close link between 
tumor glucose metabolism and altered cellular redox status, 
which may be further manipulated by ionizing radiation. 
Radiosensitization by 2DG may therefore be partially explained 
by the decreased antioxidant capacity after 2DG treatment 
[5,8,9], as well as inhibition of ATP-dependent DNA repair [12].
We sought to determine the ability of 2DG to sensitize 
prostate cancer cells to experimental radiotherapy in 
monolayer and 3-dimensional cultures and to assess the role 
of cell cycle regulation in 2DG-induced radiosensitization.
Materials and Methods
Reagents
All cell culture media and supplements were purchased 
from Life Technologies (Paisley, UK), unless stated otherwise. 
All other chemicals, including 2DG, were from Sigma-Aldrich 
(Dorset, UK).
Tissue Culture
Human prostate cancer cell lines, PC3 and LNCaP, were 
obtained from American Type Culture Collection (Manassas, 
VA, USA) and were used in this study for less than 6 months 
after resuscitation. PC3 cells were maintained in F12K medium 
supplemented with 10% (v/v) fetal bovine serum (Autogen 
Bioclear, Wiltshire, UK), 2 mM L-glutamine, 0.1 mM sodium 
pyruvate and 10 µg/ml gentamicin. LNCaP cells were maintained 
in RPMI 1640 medium supplemented with 10% (v/v) fetal 
bovine serum (Hyclone, Fisher Scientific, UK), 1% (v/v) HEPES, 
1% (v/v) D-glucose, 1 mM sodium pyruvate, 4 mM L-glutamine, 
10 µg/ml gentamicin.
Clonogenic Survival Assay
PC3 cells were seeded in 25 cm2 flasks at 105 cells/flask.
When cultures were in exponential growth phase, medium was 
removed and replaced with fresh medium containing drug. 
Cells were irradiated using an X-Strahl RS225 X-ray irradiator at 
a dose rate of 1.6 Gy per minute. After treatment for 24 h, cells 
were seeded for clonogenic survival assay as previously 
described [13,14]. Cells were incubated at 37°C in 5% CO2for 13 
days. Colonies were fixed in methanol, stained with crystal 
violet solution and colonies of at least 50 cells were counted.
Multicellular Spheroid Growth Assay
Multicellular tumor spheroids consisting of LNCaP cells 
were obtained using the liquid overlay technique [15]. 
Spheroids were initiated by inoculating cells into a plastic flask 
coated with 1% (w/v) agar. After 3 days, aliquots of spheroids 
were transferred to sterile plastic tubes and centrifuged at 12 
x g for 3 min. Thereafter, spheroids were irradiated or re-
suspended in serum-free culture medium containing 2DG. 
After treatment, the spheroids were washed twice and those 
of approximately 100 µm in diameter were transferred 
individually into agar-coated wells of 24-well plates, as 
previously described [16]. Individual spheroid growth was 
monitored twice per week for three weeks using an inverted 
phase-contrast microscope connected to an image acquisition 
system. Two perpendicular diameters, dmax and dmin, were 
measured using image analysis software (Image J) and the 
volume, V (mm3) was calculated, as previously [16], using the 
formula: V = × dmax × dmin² / 6. The area under the V/V0 
versus time curve (AUC) was calculated for individual spheroids 
using trapezoidal approximation.
Cell Cycle Analysis
Following treatment for 6 h, LNCaP or PC3 cells were 
trypsinized, washed twice with PBS then fixed with ice cold 70% 
(v/v) ethanol. After fixation, cells were washed twice with PBS and 
re-suspended in PBS containing propidium iodide (10 μg/ml) and 
RNase A (200 μg/ml). Cells were stained for 30 min before flow 
cytometric analysis using a FACSVerse analyzer (BD Biosciences, 
Oxford, UK). Data were analyzed using FlowJo software.
Statistical Analysis
Data are presented as means ± standard error of the 
mean (SEM), unless otherwise stated, with the number of 
independent repetitions provided in the legend to each 
figure. Statistical significance was determined using Student’s 
t test. A P value < 0.05 was considered to be statistically 
significant.
Results
The ability of 2DG to enhance the radiation-induced 
clonogenic kill was assessed by clonogenic assay of PC3 cells 
(LNCaP cells did not form colonies). Simultaneous administration 
of 2DG (1-10 mM) with radiation (1-4 Gy x-rays) resulted in a 
concentration- dependent decrease in clonogenic survival. 
Surviving fractions after 2 Gy (SF2) were 0.40, 0.37, 0.27 and 0.21 
for 0, 1, 5 and 10 mM 2DG, respectively. The divergence of the 
survival curves in Figure 1 suggests that the cells were sensitized 
to radiation-induced clonogenic kill by the administration of 
2DG. The efficacy of the combination of 2DG with x-radiation 
was further evaluated in a three-dimensional model of metastatic 
prostate tumors (multicellular tumor spheroids) comprised of 
LNCaP cells (PC3 cells did not form spheroids). Radiation alone 
(2 Gy x-rays) decreased spheroid growth (Figure 2A), manifest by 
an area under the growth-time curve (AUC) of 64% of untreated 
control spheroids (Figure 2B). However, 2DG alone (10 mM) did 
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not significantly reduce spheroid growth nor did it enhance the 
radiation- induced inhibition of growth as indicated by AUC 
values of 96% and 65% for 2DG alone and in combination with 
x-rays, respectively.
Figure 1. Radiation kill curve of PC3 cells exposed to 2DG (1, 5, 10 
mM) and X-radiation (1-4 Gy), administered simultaneously. 
Clonogenic assay were performed 24 h after administration of 
treatments. Data are means ± SEM, n=3
Figure 2. The effect of radiation and 2DG, alone or in combination, 
on the growth of spheroids. Spheroids composed of LNCaP cells 
were exposed to combinations of X-rays and 2DG and 24 h later 
were transferred to agar-coated plates. (A) Spheroid volume (V/V0) 
was measured up to 21 days and (B) is expressed as area under the 
growth-time curve (AUC). Data are means ± SEM, n=3. * p<0.05 
compared to untreated controls
Cytotoxicity of 2DG was assessed in monolayer cultures of 
PC3 and LNCaP cells using the MTT assay. Our results 
demonstrated that the concentrations of 2DG used in this study 
were significantly toxic to both cell lines (Figure 3). Importantly, 
the response to 2DG did not differ significantly between cell lines.
Figure 3. Cytotoxicity of PC3 and LNCaP cells exposed to 2DG for 
24 h was assessed using MTT assay. Data are means ± SEM, n=3. * 
p<0.05 compared to untreated controls
Cell cycle analysis revealed that 2DG had no significant 
effect on cell cycle distribution of PC3 cells or LNCaP cells 
(Figure 4). However, radiation (2 Gy x-rays) induced a 
significant increase in the proportion of cells in the G2/M 
phase of cell cycle in both cell lines 6 h after treatment (Figures 
4C and 4D). This radiation-induced arrest was prevented by 
simultaneous administration of 2DG (5 or 10 mM) in both PC3 
and LNCaP cell lines.
Figure 4. Cell cycle analysis after treatment of cells with radiation 
and 2DG, alone or in combination. Cell cycle profiles of PC3 cells (A) 
untreated or (B) treated with 10 mM 2DG for 6 hours. (C) PC3 and 
(D) LNCaP cells in G2/M phase of cell cycle are shown 6 h after 
treatment with x-rays, 2DG, or simultaneous combinations of both 
treatments. Data are means ± SEM, n=3. *p<0.05 compared to 
untreated controls
Discussion
It has previously been reported that inhibition of glycolysis 
by 2DG enhanced the clonogenic kill induced by radiation 
treatment in several cancer cell lines [6-10]. Although prostate 
cancer is not characterized by glycolytic activity as high as 
many other solid cancers, increased glycolysis is observed in 
the advanced stages of the disease [17], which is the target of 
combination radiotherapy being investigated here.
Several mechanisms of radiation sensitizing action by 
2DG have been suggested, including alterations in ROS levels, 
inhibition of ATP generation, reduced antioxidant capacity 
[2,6,8,9,12]. Alterations in cell cycle progression may also 
affect sensitivity to radiation. In the Kelly neuroblastoma cell 
line, 2DG caused accumulation of cells in G1 phase of cell 
cycle, but did not affect the cycling of SK-N-SH cells [18]. We 
observed that six hours after radiation treatment, the 
proportion of cells in G2/M cells was significantly increased in 
both PC3 and LNCaP cell lines. We previously reported that 
PC3 and LNCaP cells differ in their cell cycle response to 
ionizing radiation [19]. Specifically, 24 h after irradiation of 
PC3 cells, the cell cycle distribution returned to control levels 
whereas in LNCaP cells, radiation caused an increase in G1 
phase and a decrease in G2/M phase 24 h after irradiation. As 
a single treatment, 2DG alone did not significantly alter the 
proportion of G2/M cells 6 h after administration, but the 
radiation-induced arrest was returned to control levels by 
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2DG. Furthermore, reduced DNA repair in response to 
radiation has previously been reported after administration of 
2DG [20]. Although cells in the G2/M phase are considered 
more sensitive to radiation than cells in other phases [21], it is 
possible that the prevention of cycle arrest by 2DG may result 
in entry of cells into mitosis with unrepaired DNA, resulting in 
mitotic catastrophe and cell death. This is consistent with the 
observed enhancement of radiation-induced clonogenic kill.
PC3 and LNCaP cells differ with regards to their p53 
status, inasmuch as PC3 cells harbour non-functional p53, 
whereas LNCaP harbour wild-type p53[22]. However, the 
observed effect of radiation on cell cycle distribution (G2/M 
arrest 6 h after treatment) was similar in both cell lines, 
suggesting that the ability of 2DG to prevent radiation-
induced G2/M arrest is not affect by p53 status in these cells. 
This is in contrast to a previous report suggesting that 
expression of wild-type p53 in lung cancer cell lines is 
necessary for 2DG-mediated radiosensitization [10]. 
Unfortunately, the latter report did not describe the effects of 
2DG on cell cycle. The scheduling of treatment may also 
influence the role of p53. It is noteworthy that simultaneous 
administration of treatment was used in the current study 
whereas in the investigation by Sinthupibulyakit et al10 2DG 
treatment preceded irradiation by 24h.The importance of 
drug scheduling in radiosensitization has previously been 
demonstrated by ourselves and others [13,14,19,23]. The 
cytotoxicity of 2DG to both cell lines also suggested that, 
when cultured as monolayers, the two cell lines responded in 
a similar manner.
Previous reports of the radiosensitizing effects of 2DG 
were carried out in monolayer cultures. Therefore, we sought 
to evaluate the tumor growth delay in response to the 
combination therapy in a 3-dimensional model. Multicellular 
tumor spheroids are representative of malignant metastases 
in their prevascular growth phase. The use of this model 
system can enable the determination of the dependence of 
therapeutic strategies on cycling and oxygenation status 
because they are composed of cells in various proliferative 
states - necrotic core, quiescent middle layer and rapidly 
proliferating rim [24]. We observed that concentrations up to 
10 mM (Figure 2) and 30 mM 2DG (data not shown) had no 
growth inhibitory effect. This suggests that further work is 
required to determine the reasons for this lack of effect of 2DG 
on spheroids and whether 2DG is the most appropriate 
glycolytic inhibitor to be used in combination with radiotherapy. 
It is possible that the observed lack of inhibition of spheroid 
growth by 2DG was caused by differences in drug penetration, 
oxygenation and other microenvironmental factors of the 
various layers within the spheroid. This is a commonly observed 
feature of multicellular spheroids and results in their relative 
resistance to experimental therapies [25].
Conclusion
In conclusion, we report that the glycolytic inhibitor 2DG 
sensitized prostate cancer cells to experimental radiotherapy 
in monolayer cell culture and suggest a possible mechanism 
of interaction involving the prevention of cell cycle arrest. 
However, our preliminary experiments indicate that the 
combination was not effective in 3-dimensional tumor models 
and that further work is required in order fully assess the 
potential for this means of radiosensitization.
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